European Neuromuscular Centre Mid-Career Mentoring Programme Now Open
The European Neuromuscular Centre (ENMC) Mid-Career Mentoring Programme is now open for the third round of mentee candidates!
About the Programme
The programme has been developed for people who wish to seek mentoring in order to become independent researchers and/or potential future leaders in the NMD field. These individuals will be at the stage in their careers where they are developing their own research plans and are establishing their research teams and collaborative networks worldwide.
Feedback from first-year mentees
First-year mentees completed a survey on their mentoring programme experience, with results showing that the programme was extremely beneficial: the mentees were satisfied, well-matched with their mentors, and saw improvement in skills they wanted to improve (such as networking, self-confidence, delegation of work, communicating and presenting themself and securing a good work-life balance). NMD4C members who have participated in the programme as mentors in the past include Dr. James Dowling, Dr. Cynthia Gagnon, and Dr. Hanns Lochmüller.
How to apply for the ENMC Mentoring Programme
If you are interested in the mentoring programme, please find here a link to the ENMC webpage and to videos illustrating the experiences of one mentee and one mentor, which may inspire you to apply as a mentee or mentor in this ENMC programme!
The applications can be submitted to with a deadline of 1 July 2023: Guidelines – ENMC.
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.